Trial results

Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

NCT07275697 on ClinicalTrials.gov · last registry update 2026-08-10

An unusually large phase 4: 200 participants, more than double the 72 typical for the stage. Due to report 30 December 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Emma Svennberg

Sponsor type

Other

Enrollment

200

Started

2026-03-23

Primary completion

2028-12-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Arrhythmia-free survival at 12 months after catheter ablation, excluding the 3-month blanking period, with recurrence defined as any ILR-detected AF, atrial flutter, or atrial tachycardia ≥30 seconds.

Conditions studied

Atrial Fibrillation (AF) · Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.